PMRT ASTRO-ASCO-SSO Guideline

Consensus

PMRT ASTRO-ASCO-SSO Guideline

ForAdults with breast cancer undergoing mastectomy, upfront or after NST

TL;DRPMRT recommended for pN1 (Strong/High) and post-NST cT4/cN2-3 or ypN+; conditional for ypN0 after cT1-3N1/cT3N0; moderate hypofractionation preferred.

Why it mattersRadiation oncology

The pN1 omission remark is written for pts after ALND, so it does not directly cover the SLNB-only axilla now common in practice. Moderate hypofractionation is preferred with or without reconstruction, and IMN coverage is individualized by tumor location, size and nodal extent, which moves fractionation and nodal-volume defaults for most PMRT cases.

Monday clinic

In cT1-3N1 or cT3N0 disease converting to ypN0 after NST, this frames PMRT as a shared decision, with omission reasonable at ypT0N0; it does not extend to initial cT4 or cN2-3, where PMRT stands regardless of response.

12 details 5 trials watching

Design

Multidisciplinary ASTRO-ASCO-SSO task force answering four key questions via systematic review and a predefined consensus methodology. Inclusion required ≥50 pts for RCTs/meta-analyses and ≥100 for nonrandomized or retrospective studies; retrospective studies excluded for KQ1. Reviewed by 17 peer reviewers plus public comment.

Population & inclusion

Adults (≥18 years) with breast cancer undergoing mastectomy, upfront or after NST. Out of scope: inflammatory breast cancer, DCIS after mastectomy, locoregional recurrence, reirradiation, oligometastatic or palliative disease, phyllodes and breast sarcoma.

Radiotherapy

PMRT defined as chest wall/reconstructed breast plus ipsilateral regional nodes, including IMNs. Moderate hypofractionation preferred; conventional fractionation acceptable in rare cases, and an equal option with reconstruction. CT-based 3D-CRT, IMRT when 3D-CRT falls short, DIBH, bolus only for skin involvement, positive superficial margins or LVI.

vs leading data

The pN1 recommendation rests on the EBCTCG meta-analysis, which the panel notes was limited to trials initiated by 1995 and predates HER2-directed therapy and immunotherapy. The ypN0 recommendation draws on ACOSOG Z1071 analyses, the NSABP B-51/RTOG 1304 primary-outcomes abstract, and the RAPCHEM registry.

Applies to

adults undergoing mastectomy for invasive breast cancer with curative intent, upfront or after NST

Does not represent inflammatory disease, recurrent disease, reirradiation, or oligometastatic/palliative settings.

Limitations

pT1-2N0 omission is graded Strong on Low evidence, and its exception list (TNBC, high grade, LVI, young age, central/medial tumors) is unquantified. The ypN0 Moderate grade leans on pooled secondary analyses, retrospective series and a registry. Large registry database studies were excluded throughout.

Discussion

The operative content sits in the implementation remarks, not the headline grades: pN1 omission for favorable pN1mic/low-burden pN1a, ypT0N0 omission, and chest wall alone for select pT3N0. What stays unsettled is RT for the cN1 → ypN0 pt, the only Conditional call in the post-NST table.

Results

Scenario	Recommendation	Strength	QoE
pN1	PMRT recommended	Strong	High
Any pT4	PMRT recommended, even without other risk factors	Strong	High
pT3N0	PMRT conditionally recommended	Conditional	High
pT1-2N0	PMRT not recommended	Strong	Low
Positive margins, no other indication	Chest wall/reconstructed breast alone	Conditional	Expert opinion

Scenario	Recommendation	Strength	QoE
Initial cT4 or cN2-3	PMRT regardless of pathologic response	Strong	Moderate
ypN1	PMRT recommended	Strong	Moderate
cT1-3N1 or cT3N0 → ypN0	PMRT conditionally recommended	Conditional	Moderate
cT1-2N0 → ypN0	PMRT not recommended	Strong	Moderate
Positive margins after NST	PMRT recommended	Strong	Expert opinion

Scenario	Recommendation	Strength	QoE
Any PMRT	Chest wall/reconstructed breast + axillary, supra/infraclavicular, IMNs	Strong	High
No reconstruction	Moderate hypofractionation	Strong	High
Reconstruction	Moderate hypofx (preferred) or conventional	Strong	Moderate (hypofx)
T4 or close/positive margins	Chest wall/scar boost	Conditional	Low
Nodal disease not surgically addressed	Nodal boost	Strong	Expert opinion

Rationale

Joint ASTRO-ASCO-SSO guideline from a 104-study systematic review; output is graded recommendations, not a measured outcome. Reframes indications around NST response.

Open questions

PMRT omission in cN1 converting to ypN0 after NST

not yet De-escalation of RNI in Breast Cancer Patients With pN0 After Neoadjuvant Therapy Phase NA

n=100 · primary completion 2028-06 · RNI de-escalation in biopsy-proven cN1 → ypN0 after NST
Hypofractionated PMRT toxicity with reconstruction

recruiting Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction Phase 3

n=506 · primary completion 2029-03 · phase 3 43.5/15 vs 50/25 after prosthetic reconstruction

recruiting Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based Reconstruction Phase NA

n=534 · primary completion 2033-10 · hypo vs conv PMRT post-implant; NI unplanned reoperation
IMN irradiation benefit in the modern systemic era

not yet Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer Phase 3

n=1760 · primary completion 2032-07 · phase 3 ± IMNI in ypN+ after NST; DFS primary

recruiting Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy Phase 3

n=722 · primary completion 2032-07 · phase 3 IMNI vs none, ypN+ post-NAC; DFS primary

📚 Sources · 📄 1 paper

📄 PAPER Jimenez, Rachel B.; Abdou, Yara; Anderson, Penny et al. · Journal of Clinical Oncology (2025-10)

Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline

doi

Abstract

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete ASCO and ASTRO disclaimers in Appendix 1 (online only) for more. PURPOSE This guideline provides recommendations on use of postmastectomy radiation therapy (PMRT) in breast cancer treatment. Updated recommendations detail indications for PMRT in the upfront surgical setting and after neoadjuvant systemic therapy, and provide guidance on appropriate target volumes, dosing, and treatment techniques. METHODS A multidisciplinary American Society for Radiation Oncology–ASCO–Society of Surgical Oncology task force addressed four key radiation therapy (RT) questions in patients with breast cancer who undergo mastectomy: (1) indications for PMRT after upfront surgery, (2) indications for PMRT after neoadjuvant systemic therapy followed by surgery, (3) appropriate PMRT volumes and dose-fractionation regimens, and (4) treatment techniques. Recommendations were based on a systematic review and created using a predefined consensus-building methodology for quality of evidence grading and strength of recommendation. RECOMMENDATIONS After upfront mastectomy, PMRT is indicated for most patients with node-positive breast cancer and select patients with node-negative disease. PMRT is also recommended after neoadjuvant systemic therapy for patients presenting with locally advanced disease and for those with residual nodal disease at the time of surgery. PMRT is conditionally recommended for patients with cT1-3N1 or cT3N0 breast cancer with pathologically negative nodes after neoadjuvant systemic therapy (ypN0). When PMRT is delivered, treatment to the ipsilateral chest wall or reconstructed breast and regional lymphatics is recommended, with moderate hypofractionation preferred, but with conventional fractionation approaches acceptable in rare cases. Computed tomography–based volumetric treatment planning with 3-dimensional conformal RT is recommended, with intensity-modulated RT advised when three-dimensional conformal RT is unable to achieve treatment goals. Deep inspiration breath-hold techniques are also recommended for normal tissue sparing. For patients with skin involvement, positive superficial margins, and/or lymphovascular invasion, use of a bolus is recommended, but routine use of tissue-equivalent bolus is not recommended. Additional information is available at www.asco.org/breast-cancer-guidelines .

Radiation Curative Consensus / guideline Consensus

The longer read

The structural change here is that the PMRT decision is now organized around response to neoadjuvant systemic therapy as much as around pathology after upfront surgery, and the panel grades those two pathways differently. The upfront recommendations draw on randomized trials and the EBCTCG meta-analysis and mostly carry High quality of evidence. The post-NST recommendations top out at Moderate, and the one that matters most in daily practice, the cT1-3N1 or cT3N0 pt who converts to ypN0, is the only Conditional call in that table. That grade looks honest. The evidence behind it is mostly pooled secondary analyses of systemic-therapy trials, retrospective series such as KROG 12-05, and the RAPCHEM registry, with the NSABP B-51/RTOG 1304 primary-outcomes abstract cited next to them. A reader should treat the ypN0 recommendation as a framework for shared decision-making, not a resolved question.

The pN1 recommendation shows the gap between a grade and its implementation remarks. It is Strong with High evidence, yet the remark allows omission for pN1mic or low-burden pN1a with favorable features. The panel itself says the EBCTCG base was limited to trials initiated by 1995 and did not use current systemic regimens, which it credits with added locoregional control and DFS benefit. So the grade reflects the older trials, and the remark is where modern de-escalation sits. There is a catch: the remark is written for pts after ALND. The guideline also cites the shift toward sentinel node biopsy and targeted axillary dissection, so the population the remark explicitly covers is shrinking. For a pN1a pt staged by SLNB alone, the document does not speak directly, and that is where tumor-board disagreement will concentrate.

The pT1-2N0 recommendation is Strong on Low evidence. ASTRO's grading system allows this; its own table states that a lower quality of evidence does not make a recommendation conditional. The practical meaning is that omission is the default, with an exception list (triple-negative, high grade, LVI, young age, central or medial tumors) that names no threshold or combination. Readers should not mistake the Strong label for strong data.

On volumes and dose, the guideline is more decisive. Treating the chest wall or reconstructed breast with regional lymphatics, IMNs included, is Strong with High evidence, but IMN coverage is left to tumor location, size and nodal extent. That keeps the main IMN judgment with the treating physician. Moderate hypofractionation is preferred both without reconstruction (High) and with reconstruction (Moderate). For a practice still defaulting to conventional fractionation after implant or autologous reconstruction, this is the recommendation most likely to change routine planning. Routine bolus is not recommended, and bolus is limited to skin involvement, positive superficial margins or LVI. That should cut skin toxicity in centres that bolus by habit.

What the guideline does not settle: the boost recommendations for T4 or close/positive margins are Conditional on Low evidence, and the nodal boost for nodal disease not surgically addressed rests on expert opinion. Inflammatory disease, recurrence and reirradiation are out of scope. The literature search closed in October 2024, so any later maturation of the ypN0 trials will need to be weighed against the Conditional grade rather than read as contradicting a firm position.